Last reviewed · How we verify
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine (Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine TARGET | Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine | Sanofi Pasteur, a Sanofi Company | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine CI watch — RSS
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine CI watch — Atom
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine CI watch — JSON
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/attenuated-measles-mumps-rubella-inactivated-hep-a-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab